FDA orders starker warnings on opioid painkillers

The Food and Drug Administration is requiring stronger warning labels on prescription painkillers like OxyContin, in the government's latest attempt to reduce overdose deaths caused by the long-acting medications.

The changes announced Tuesday are designed to remind doctors and patients about the fatal risks of misusing and abusing opioid pain relievers, which include extended-release forms of oxycodone, hydrocodone and morphine.

The new label emphasizes that long-acting opioids are only for patients with "around-the-clock" pain that cannot be treated with over-the-counter medications or immediate-release opioids.

The FDA has issued a number of warnings about the dangers of in recent years but with little effect. Inappropriate use of opioids caused more than 16,650 in 2010, up more than 12 percent from 2008.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

US panel opposes pure hydrocodone painkiller

Dec 09, 2012

(AP)—U.S. government health experts overwhelmingly voted against a stronger version of hydrocodone on Friday, questioning the need for a new form of one of most widely abused prescription painkillers.

Opioid prescription is on the increase

Feb 12, 2013

More and more opioids are being prescribed for pain relief in Germany. This is the conclusion arrived at by Ingrid Schubert, Peter Ihle, and Rainer Sabatowski, whose study of a sample of inhabitants of the state of Hesse ...

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments